Search | Clinical Trials Finder

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-04603629, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • Wichita, Kansas + 1 more

Conditions: Alzheimer Disease
Interventions: Mevidalen, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Carlsbad, California + 40 more

Conditions: Diabetes Mellitus, Atrial Fibrillation
Interventions: Dapagliflozin 10Mg Tab, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 768 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 61
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more

Conditions: Chronic Kidney Disease
Interventions: MEDI8367, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Postpartum Smoking Relapse
Interventions: Bupropion Extended Release Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Achilles Tendinopathy
Interventions: NGI226, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Tucson, Arizona • Deerfield Beach, Florida • Houston, Texas

Conditions: Ulcerative Colitis
Interventions: vedolizumab, Placebo; Drug · Other
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 102
States / cities: Birmingham, Alabama • Los Angeles, California • Montebello, California + 82 more

Conditions: Covid19, SARS-CoV Infection, ARDS, ARDS, Human
Interventions: Instilled T3, Placebo Therapy; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1999
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Rochester, New York + 1 more

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 38
States / cities: Chula Vista, California • La Jolla, California • Lancaster, California + 34 more

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Conditions: Pain Management
Interventions: Bupivacaine/Epinephrine, Saline; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer Metastatic
Interventions: LY3023414, Enzalutamide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Homewood, Alabama • Fayetteville, Arkansas • Marina del Rey, California + 31 more

Conditions: Healthy
Interventions: TD-1473 for SAD, Placebo for SAD, TD-1473 for MAD, Placebo for MAD; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Spinal Cord Injury, Pain
Interventions: botulinum toxin A, placebo; Drug · Other
Lead sponsor: Craig Hospital; Other
Eligibility: 15 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions: Fecal Microbiota Transplant (FMT), Placebo; Biological
Lead sponsor: Stacy A. Kahn; Other
Eligibility: 5 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: COVID-19, Lymphocytopenia
Interventions: CYT107, Placebo; Drug
Lead sponsor: Revimmune; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Menopausal Hot Flashes, Menopausal Women
Interventions: ashwagandha root, ashwagandha root and leaf, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 40 Years to 55 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Huntsville, Alabama

Conditions: Osteoporosis
Interventions: lasofoxifene, raloxifene, Placebo; Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 48 Years to 75 Years · Female only
Enrollment: 540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 72
States / cities: Albany, California • Berkeley, California • La Jolla, California + 49 more

Conditions: Clostridial Infection, Dysbiosis, Probiotic Therapy
Interventions: Fecal Microbiota Transplantation (FMT), Saline; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Decatur, Georgia • Durham, North Carolina • Nashville, Tennessee

Conditions: Aging
Interventions: Probiotic capsule and Fiber Sachet, Probiotic capsule and Placebo sachet, Placebo capsule and Fiber Sachet, Placebo capsule and Placebo sachet; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 65 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Gainesville, Florida • Ocala, Florida

Search by objective public record fields.

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease

Bupropion for the Prevention of Postpartum Smoking Relapse

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers

Efficacy & Safety of TD-1473 in Ulcerative Colitis

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair

Local Anesthesia for Facial Fractures

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury.

Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, Placebo Controlled Clinical Trial

Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss

Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD)

The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women